I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Muroyama, Ryosuke
96
results:
Search for persons
X
Format
Online (96)
Mediatypes
Articles (Online) (49)
OpenAccess-fulltext (47)
Sorted by: Relevance
Sorted by: Year
?
1
Hyperprogressive disease during atezolizumab plus bevacizum..:
Yumita, Sae
;
Ogasawara, Sadahisa
;
Nakagawa, Miyuki
...
BMC Gastroenterology. 23 (2023) 1 - p. , 2023
Link:
https://doi.org/10.1186/..
?
2
Cabozantinib for Advanced Hepatocellular Carcinoma in the L..:
Kanzaki, Hiroaki
;
Ogasawara, Sadahisa
;
Okubo, Tomomi
...
Drugs - Real World Outcomes. 10 (2023) 4 - p. 513-520 , 2023
Link:
https://doi.org/10.1007/..
?
3
Miglustat, a glucosylceramide synthase inhibitor, mitigates..:
Iwanaga, Terunao
;
Chiba, Tetsuhiro
;
Nakamura, Masato
...
Biochemical and Biophysical Research Communications. 642 (2023) - p. 192-200 , 2023
Link:
https://doi.org/10.1016/..
?
4
Use of ramucirumab for various treatment lines in real-worl..:
Kanogawa, Naoya
;
Ogasawara, Sadahisa
;
Maruta, Susumu
...
BMC Gastroenterology. 23 (2023) 1 - p. , 2023
Link:
https://doi.org/10.1186/..
?
5
Alteration of the tumor microenvironment by pharmacological..:
Qiang, Na
;
Ao, Junjie
;
Nakamura, Masato
...
International Immunopharmacology. 118 (2023) - p. 110068 , 2023
Link:
https://doi.org/10.1016/..
?
6
The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus ..:
Kanzaki, Hiroaki
;
Chiba, Tetsuhiro
;
Kaneko, Tatsuya
...
International Journal of Molecular Sciences. 23 (2022) 14 - p. 7878 , 2022
Link:
https://doi.org/10.3390/..
?
7
Liver biopsy technique in the era of genomic cancer therapi..:
Ozeki, Yusuke
;
Kanogawa, Naoya
;
Ogasawara, Sadahisa
...
International Journal of Clinical Oncology. 27 (2022) 9 - p. 1459-1466 , 2022
Link:
https://doi.org/10.1007/..
?
8
Baseline soluble MICA levels act as a predictive biomarker ..:
Arai, Jun
;
Otoyama, Yumi
;
Fujita, Ken-ichi
...
BMC Cancer. 22 (2022) 1 - p. , 2022
Link:
https://doi.org/10.1186/..
?
9
Durvalumab with or without tremelimumab combined with parti..:
Ogasawara, Sadahisa
;
Koroki, Keisuke
;
Makishima, Hirokazu
...
BMJ Open. 12 (2022) 4 - p. e059779 , 2022
Link:
https://doi.org/10.1136/..
?
10
Antiviral Compounds Screening Targeting HBx Protein of the ..:
Ma, Yaojia
;
Nakamoto, Shingo
;
Ao, Junjie
...
International Journal of Molecular Sciences. 23 (2022) 19 - p. 12015 , 2022
Link:
https://doi.org/10.3390/..
?
11
Effect of Atezolizumab plus Bevacizumab in Patients with He..:
Ogawa, Keita
;
Kanzaki, Hiroaki
;
Chiba, Tetsuhiro
...
Journal of Cancer. 13 (2022) 8 - p. 2656-2661 , 2022
Link:
https://doi.org/10.7150/..
?
12
A diet-induced murine model for non-alcoholic fatty liver d..:
Sakuma, Takafumi
;
Nakamura, Masato
;
Chiba, Tetsuhiro
...
Laboratory Investigation. 102 (2022) 10 - p. 1150-1157 , 2022
Link:
https://doi.org/10.1038/..
?
13
Fusion HBx from HBV integrant affects hepatocarcinogenesis ..:
Muroyama, Ryosuke
;
Nakagawa, Ryo
;
Matsubara, Yasuo
...
Virus Research. 315 (2022) - p. 198787 , 2022
Link:
https://doi.org/10.1016/..
?
14
EZH1/2 inhibition augments the anti-tumor effects of sorafe..:
Kusakabe, Yuko
;
Chiba, Tetsuhiro
;
Oshima, Motohiko
...
Scientific Reports. 11 (2021) 1 - p. , 2021
Link:
https://doi.org/10.1038/..
?
15
Changes in therapeutic options for hepatocellular carcinoma..:
Ogasawara, Sadahisa
;
Koroki, Keisuke
;
Kanzaki, Hiroaki
...
Liver International. 42 (2021) 9 - p. 2055-2066 , 2021
Link:
https://doi.org/10.1111/..
1-15